When assessed separately , eyes with qualitative OCT ( Months 5 and 8 ) or fundus fluorescein angiography ( months 3 and 5 ) inactivity maintained vision gain from baseline at month 24 , while those with leakage not only lost initial vision gains achieved by intraocular ranibizumab but also had net vision losses from baseline at month 24 .
